NVCT
HealthcareNuvectis Pharma, Inc.
$8.53
+$0.02 (+0.24%)
Jan 5, 2026
Price History (1Y)
Analysis
Nuvectis Pharma, Inc. is a biotechnology company in the healthcare sector with 13 employees. The company has a market capitalization of $218.50M. The financial health of Nuvectis Pharma indicates significant losses, with net income totaling -$27,805,000 over the trailing twelve months. Margins are also negative, at 0.0% for gross margin, operating margin, and profit margin. Returns on equity and assets are similarly unfavorable, at -145.0% and -62.4%, respectively. The company has a current ratio of 3.07, indicating that it can cover its short-term obligations. Cash reserves stand at $35.44M. The valuation context for Nuvectis Pharma is characterized by a negative forward P/E ratio of -8.89. The price to book ratio is 9.11.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Visit website →Key Statistics
- Market Cap
- $218.50M
- P/E Ratio
- N/A
- 52-Week High
- $11.52
- 52-Week Low
- $5.34
- Avg Volume
- 99.58K
- Beta
- -0.30
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 13